Related Experiment Video
Updated: Aug 11, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management
J D Fuller1, A McGeer, D E Low
1Department of Microbiology, Toronto Medical Laboratories and Mount Sinai Hospital, University of Toronto, 600 University Avenue, M5G 1X5, Toronto, Ontario, Canada.
Abstract:
Community-acquired pneumonia is the most common infectious disease that causes death, with Streptococcus pneumoniae remaining the leading causative pathogen. The worldwide incidence of infections caused by pneumococci resistant to penicillin, macrolides, and other antimicrobial agents has increased at an alarming rate during the past 2 decades. Yet, these agents are still used as first-line empirical therapy in the outpatient setting. There are several reasons for this, including the infrequency of making a pathogen-specific diagnosis, the failure of studies to demonstrate the relevance of resistance, and the infrequency with which clinicians recognize clinical failures. Despite this, there is mounting evidence that supports the practice of using high doses of some antimicrobial agents, a more active antimicrobial agent within a class, or switching to another class of antimicrobial agents when a patient is identified as being at an increased risk of infection with a resistant pneumococcus. There is now information that will allow the physician to identify not only the patient at risk for infection with a resistant pneumococcus but also the antimicrobial class and, in some cases, the agent within the class to which the organism is more likely to be resistant. This will allow clinicians to better define optimal therapy for patients with community-acquired pneumonia.
Insights
Community-acquired pneumonia (CAP) caused by resistant Streptococcus pneumoniae is rising. Evidence supports adjusting antibiotic therapy based on resistance risk for better patient outcomes.
Area of Science:
- Infectious Diseases
- Antimicrobial Resistance
- Pneumonia Research
Background:
- Community-acquired pneumonia (CAP) is a leading cause of infectious disease death.
- Streptococcus pneumoniae is the primary pathogen, with increasing resistance to common antibiotics.
- Current empirical antibiotic therapy for CAP often fails to account for rising resistance rates.
Purpose of the Study:
- To review evidence supporting tailored antimicrobial therapy for CAP.
- To provide guidance on identifying patients at risk for resistant pneumococcal infections.
- To inform optimal antibiotic selection based on pathogen resistance profiles.
Main Methods:
- Literature review of studies on antimicrobial resistance in Streptococcus pneumoniae.
- Analysis of factors influencing clinical outcomes in CAP.
- Examination of guidelines for empirical and targeted antibiotic therapy.
Main Results:
- Increasing rates of penicillin and macrolide resistance in Streptococcus pneumoniae worldwide.
- Challenges in diagnosing specific pathogens and recognizing clinical treatment failures.
- Evidence supports using higher antibiotic doses, more active agents, or alternative classes for resistant infections.
Conclusions:
- Clinicians can identify patients at risk for resistant pneumococcal CAP.
- Understanding resistance patterns allows for better-informed, optimized antibiotic selection.
- Tailoring therapy improves treatment efficacy for community-acquired pneumonia.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
03:53Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:25Mechanism of Antibiotic Resistance in MRSA
01:29Pneumonia I: Introduction